photo de profil d'un membre

Regis VILLET

Business Unit Director - Tech & bioPharma

Situation professionnelle

En recherche active

Souhait professionnel

Poste
CXO
Experience
15-20 ans
Rémuneration
De 101 à 200K€
Type de contrat
CDI
Mobilité
69 Rhône - France
Fonctions
- Directeur Général Adjoint 
- Directeur Général 
- Directeur 
Secteurs
- Industrie Agro-alimentaire/Tabac
- Industrie Chimique/Pharmacie/Plastiques
- Autre

Résumé

My blended background, coupling scientific (Master in Science, Ph.D, HDR) and managerial skills (Executive MBA), along with 17 years of professional experience in international settings and team management (Bioaster, Havard University, HUG, HCL), allows me to approach complex challenges in an integrated way. I am passionate about leveraging scientific advancements by translating them into potential business opportunities. This combination of skills guides me in strategizing, building strategic alliances, and tackling international challenges, all with a holistic vision.

Expériences professionnelles

Ceo & founder

RVLT Life Sciences Advisors , Lyon

Depuis le 01 juin 2025

Head of business development

Theremia , Paris

Depuis le 01 mai 2026

Cso

Allergen Alert , Lyon

Depuis le 01 novembre 2025

Business development & strategic alliance management

BIOASTER

De Janvier 2022 à Juin 2025

As a Business Developer and Alliance Manager at BIOASTER, I leverage my dual background in science and business to forge strategic alliances, manage key portfolios, and stimulate innovation in microbiology. I am committed to adding value to our partners, clients, and BIOASTER while promoting the forefront of the digital revolution, including Artificial Intelligence solutions.

Key Responsibilities:

- Identification and management of new strategic partnerships
- Creation of synergies and establishment of strategic collaborations
- Management of key portfolios
- Development of collaborative projects tailored to our clients' specific needs
- business development plan strategy
- Contract negotiation
- Adding value to our clients and partners through innovative project implementation
- Development of international collaborations
- Maintaining strong relationships with our clients
- Utilizing Artificial Intelligence and the digital revolution to enhance BIOASTER's activities

I adopt a client-centered approach, aiming to provide competitive advantages through innovative solutions that meet our partners' strategic needs. My goal is to accelerate research, overcome technological hurdles, and enable the rapid market launch of solutions beneficial for patients.

Head of business development - antimicrobial program

BIOASTER , Lyon

De Septembre 2021 à Août 2025

Head, microbiology unit

BIOASTER

De Janvier 2017 à Décembre 2021

In this position, I develop and manage the activity of the Microbiology Unit (up to 15 collaborators) and contribute to the scientific strategy & development of the Institute in conjunction with the Programs (Antimicrobials, Vaccines, Microbiota and Diagnostic). Both internally and externally, I create the conditions for technological innovation and scientific emulation in the field of infectious diseases by creating effective synergies. Among partners, both academic and industrial, I promote the integration of know-how and technological offer into the institute's collaborative projects, in response to the partners needs.

Group head

International Center for Infectiology Research (CIRI)

De Janvier 2016 à Décembre 2017

Team lead related to biofilm-related clinical and industrial research programs
♦ 1 patent : biofilmCare FR1659459 - PCT/FR2017052646
Method and device for preparing and washing biofilms for analysis. This non-aggressive and non-destructive washing technique preserves the integrity of the biofilms. It allows the in-depth study of newly formed (native) or mature biofilms, by qualifying and quantifying the living bacteria making up the biofilm. It constitutes the ideal basis for an analysis of biofilms in various fields, from health to the food industry, whether of bacterial, fungal or algal origin.

2 peer reviewed publications :
♦ “A steam-based method to investigate biofilm“, Tasse J, Cara A, Saglio, M, Villet R & Laurent F. Sci. Rep. 2018
♦ “Processing and antibacterial properties of chitosan-coated alginate fibers“, Dumont M, VilletR, Guirand M, Montembault A, Delair T, Lack S, Barikosky M, Vrepet A, Alcouffe P, Laurent F, David L. Carbohydrate Polymers 2018

Research associate

Harvard Medical School and Massachusetts General Hospital

De Janvier 2009 à Décembre 2015

Research and team lead related to the identification of antimicrobial resistance mechanisms in Staphylococcus aureus
7 peer reviewed publications :
♦ “Functions of a GyrBA Fusion and the Interaction with QnrB and Quinolones”, Chen C, Villet R, Jacoby GA, Hooper DC. AAC. 2015
♦ “Genes contributing to Staphylococcus aureus success in abscess and infection related ecologies”, Valentino M, Foulston L, Sadaka S, Kos V,Villet R, Santa Maria Jr. J, Lazinski D, Camilli A, Walker S, Hooper D and Gilmore M. MBio. 2014
♦ “Regulation of Expression of abcA and Its Response to Environmental Conditions”, Villet R, Truong-Bolduc QC, Wang Y, Estabrooks Z and Hooper D. J Bacteriol. 2014
♦ “Role of Tet38 Efflux Pump in S. aureus Survival and Resistance to Fatty acids”, Truong-Bolduc QC, Villet R, Estabrooks Z, Routray A, Maira-Litran T, Onodera Y and Hooper D. J Infect Dis 2014
♦ “Moenomycin Resistance Mutations in Staphylococcus aureus Reduce Peptidoglycan Chain Length and Cause Aberrant Cell Division”, Rebets Y, Lupoli T, Qiao Y, Schirner K, Villet R, Hooper D, Kahne D, Walker S. ACS Chem Biol 2014
♦ "Cochlin produced by follicular dendritic cells promotes anti-bacterial innate immunity" Py B, Gonzalez S, Long K, Kim Y, Yao J, Zhu H, Degauque N, Villet R, PatrickYL, Kim MS, Gadjeva M, Pier G, Carroll M, Yuan J. Immunity 2013
♦ “Reduced Aeration Affects the Expression of the NorB Efflux Pump of Staphylococcus aureus by Posttranslational Modification of MgrA” Truong-Bolduc QC, Hsing LC, Villet R, Bolduc GR, Estabrooks Z, Taguezem GF and Hooper DC. J Bacteriol. 2012

Research fellow

HUG - Hôpitaux Universitaires de Genève

De Janvier 2007 à Décembre 2009

Research lead related to the identification of antimicrobial resistance mechanisms in Staphylococcus aureus
1 peer reviewed publication :
♦ “Impact of ciprofloxacin exposure on Staphylococcus aureus genomic alterations linked with emergence of rifampin resistance” Didier JP, Villet R, Huggler E, Lew DP, Hooper DC, Kelley WL, Vaudaux P. Antimicrob Agents Chemother. 2011

Formations complémentaires

HDR

UCBL - Microbiologie

0000 à 2020

Doctorat

UPMC - Biochimie & Biologie Moléculaire

0000 à 2007

Master

Université Paris Descarte - Pharmacochimie

0000 à 2003

Associations

PLCF

https://plcf.org/

membre

Harvard Club de France

https://www.harvardclub.fr/

membre

LIONS Clubs Intenational

https://www.lionsclubs.org/fr

membre

Parcours officiels

Emlyon business school – Executive MBA – MBA – 2023

Compétences

Academic Administration
Change Management
Négociations stratégiques
Strategic partnership
Digital Health
Business
Healthtech
Business development
Microbiology
Molecular Biology
Biochemistry
Infectious Diseases
Life Sciences
Biotechnology
Project Management
Management
Drug Discovery
R&D
Biotechnologie
Innovation
Sciences de la vie
Stratégie d’entreprise
Réflexion stratégique
Artificial Intelligence (AI)
Gestion du changement
leadership

Centres d'intérêt

  • Trekking